|Videos|November 26, 2018
Patient Selection and Safety With TNF Inhibitors
Advertisement
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- AML Survival After 3 Years in Remission Comparable With General Population
September 20th 2025
- CSU More Burdensome in Female Patients, Especially in Midlife
September 20th 2025
- Rocatinlimab AD Combo Therapy Safe, Effective Over 24 Weeks
September 19th 2025